Your Antibodies for Therapy
Providing the antibodies to meet
your target validation assays

MAbQi delivers readily developable human antibodies for your pipeline


Recognized team
of experts in antibody discovery

Proprietary in vitro
optimized human library

100% delivery
track records of today*
(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, … (many of them cross-reactive human/mouse)

TECHNOLOGY
- Proprietary synthetic Ab library
- In vitro screening methods validated on :
- - integral membrane proteins
- - soluble proteins
- - peptides
ABOUT US
Mabqi, founded upon best
in class technology from Inserm,
is a biotech company with an integrated
approach to develop human antibodies.

LATEST NEWS
New article about Mabqi
Follow Pierre Martineau, Director of Research at Inserm and have a look at Mabqi’s origin as creator of tailored antibodies. Know more about how started the company, what are its economic model and its ambitions for 2023. Read the article
Are you planning on attending #AIS2022?
Come and visit Mabqi at booth 15 during the 10th Antibody Industrial Symposium - June 28-29, 2022 in #Montpellier (France).Get all the information and register at https://aiscongress.com/
Mabqi makes a donation for the French Red Cross
Mabqi and its employees strongly condemn the Russian invasion and the war waged in Ukraine, leading to suffering and chaos in Europe. In support for the Ukrainian populations affected by the current crisis, Mabqi has decided to take actions for the French Red Cross and has donated 10 000 euros for humanitarian aid.